
Release date: 2026-01-16 17:07:57 Article From: Lucius Laos Recommended: 124
Although severe adverse reactions to Pralsetinib (brand name: Gavreto) are relatively rare, the drug may still induce certain severe side effects, requiring close monitoring during administration.
Severe allergic reactions may occur, presenting with symptoms including dyspnea or wheezing, tachycardia, fever, lymphadenopathy, facial or laryngeal edema, dysphagia, skin rash or urticaria, nausea and vomiting, dizziness, gastrointestinal colic, or arthralgia. Discontinue the drug immediately and seek medical assistance upon the onset of any of these symptoms.
In addition, the drug may cause life-threatening pulmonary inflammation (interstitial lung disease or pneumonia). Immediate medical attention is required if symptoms such as dyspnea, cough, fever, or chest pain develop.
Gavreto may also induce hypertension or exacerbate pre-existing hypertension. Contact healthcare providers promptly if there is a significant elevation in blood pressure (e.g., systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥120 mmHg) or if symptoms like severe headache, chest pain, dizziness, dyspnea, or blurred vision occur.
Hepatic injury is another potential risk, which may manifest as nausea, abdominal pain, fever, fatigue, pruritus, decreased appetite, pale stools, dark urine, or jaundice. Regular monitoring of liver function is necessary, and immediate medical consultation should be sought if relevant symptoms appear.
The drug may also increase the risk of severe hemorrhage, such as hematuria, hematemesis, melena, hemoptysis, abnormal bruising, or vaginal bleeding. Emergency medical intervention is required if accompanied by confusion, headache, or dysarthria.
Furthermore, Gavreto may trigger tumor lysis syndrome, with symptoms including nausea and vomiting, asthenia, edema, shortness of breath, muscle cramps, or seizures. Maintain adequate hydration and undergo regular blood tests during treatment. Inform healthcare providers immediately if any associated symptoms arise.
1. Before taking pralsetinib, inform your physician and pharmacist if you are allergic to pralsetinib, any other medications, or any ingredients contained in pralsetinib capsules. You may request a list of ingredients from your pharmacist.
2. Disclose all other prescription drugs, over-the-counter medications, vitamins, dietary supplements, and herbal products you are taking or planning to take to your physician and pharmacist. Your doctor may need to adjust the dosages of other medications or closely monitor for side effects.
3. The following over-the-counter drugs or herbal products may interact with pralsetinib: St. John's Wort. Be sure to inform your physician and pharmacist if you are taking this product before initiating pralsetinib treatment. Do not start any such medications during pralsetinib therapy without the consent of your healthcare provider.
4. Notify your doctor if you have a history of, or currently suffer from, pulmonary or respiratory disorders (other than lung cancer), bleeding disorders, hypertension, or renal/hepatic diseases.
Maintain a normal diet unless otherwise instructed by your physician.
If you remember a missed dose on the same day, take it as soon as possible. Then resume your regular dosing schedule. Do not take a double dose to make up for a missed one.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3502025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3512025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3922025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3252025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3002025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643